Haemonetics Forecasts 1.4% Price Hike and €12.5m FX Hit in 2026
Haemonetics expects a 1.4% price increase in 2026 and organic growth around 3%, offset by a €12.5m FX headwind from a weaker dollar. The company anticipates gradual production ramp-up in Transfusion Medicine, a catch-up in the Haemonetics business backlog, and conservative margin expansion due to hires and currency pressures.
1. 2026 Financial Guidance
Haemonetics projects a 1.4% price increase and about 3% organic revenue growth in 2026, countered by a negative foreign exchange impact of roughly €12.5m based on a weakened dollar assumption.
2. Transfusion Medicine and Backlog Recovery
Management plans a phased production ramp-up in the Transfusion Medicine segment while actively addressing a backlog in the Haemonetics business, expecting a full catch-up during the year.
3. Margin and Cost Outlook
Margin expansion is expected to be modest as the company invests in strengthening its sales team, increases short-term management incentives and navigates currency headwinds and raw material cost volatility.